Global Neuropsychiatric Disorders And Treatment Market At A CAGR Of 6.2% by 2023
Global Neuropsychiatric Disorders And Treatment Market Research Report, By Disorders (Degenerative Diseases, Neurotic Disorders, Psychosis And Others), By Treatments (Shock Treatment, Drug Treatment, Others) By End Users (Hospitals, Clinics, Research Centers And Others) – Forecast Till 2023
Pune, India – July 6, 2017 /MarketersMedia/ —
Neuropsychiatric disorders are mental disorder occur due to disturbance in the function of cerebral system. Neuropsychiatric disorders are most common in people greater than 65 yrs. of age. Increasing prevalence of neuropsychiatric disorders across the globe is the major reason for driving the market. Beside this increasing demand for the better treatment and development in the healthcare sector are the major driving factor for the growth of the market. While lack of clinical trial data for neuropsychiatric drugs and long term treatment of this diseases may restrain the growth of the market.
Geographically, North America accounts the largest market for the neuropsychiatric disorders and treatment which is slightly less than Europe. Huge population suffering from neuropsychiatric disorders in this region is the major reason for the development of the market. According to WHO the number of patients suffering from neuropsychiatric disorders will be doubled in next couple of decades due to increasing aging population in North America and Europe. Asia Pacific has the third leading market which is expecting a fastest growth in this market due to rapid development in healthcare sector and increasing demand for the better treatment of the neuropsychiatric disorders.
Get a sample report at https://www.marketresearchfuture.com/sample_request/1281 .
Global neuropsychiatric disorders and treatment market is segmented on the basis of disorders into degenerative diseases, neurotic disorders, psychosis and others. On the basis of treatments it is segmented as shock treatment, drug treatment, others and on the basis of end users it is hospitals, clinics, research centers and others
Key Players for Global neuropsychiatric disorders and treatment market
• Astrazeneca (UK)
• GlaxoSmithKline (UK)
• Universal Health Services Inc. (US)
• Biogen (US)
• Boehringer Ingelheim GmbH (Germany)
• Eli Lilly (US)
• Bristol-Meyer Squibb (US)
• Johnson & Johnson (US)
• Pfizer (US)
• Wyeth (US)
• Otsuka Holdings Co. Ltd (Japan)
• Astellas Pharma Inc. (Japan)
Browse Complete Report at https://www.marketresearchfuture.com/reports/neuropsychiatric-disorders-treatment-market-1281 .
Many factors are fueling the growth of the market. This has attracted many of the manufacturer for development of the market in this sector. Increasing in alliances amongst the leading player has helped to introduction of new and better treatment for the neuropsychiatric disorders.
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company headquartered in UK. Recently AstraZeneca has completed its collaboration with National Institute of Mental Health. This collaboration will help to discover the new and better drug treatment for distressing condition. AstraZeneca has also collaborated with Vanderbilt Center for the Neuroscience Drug Discovery which aims to discover new drug for the treatment of neuropsychiatric disorders.
Universal Health Services is an American Fortune 500 company headquartered in US. It is one of the largest hospital management companies in US. Universal Health Services is a huge company with the revenues of nearly USD 9.7 billion with the profit of more than USD 600 million.
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies headquartered in Germany. In 2016, Boehringer Ingelheim has collaborated with Saniona. This collaboration aims to develop the new treatment for the patients suffering from schizophrenia.
Get a Discount at https://www.marketresearchfuture.com/check-discount/1281 .
TABLE OF CONTENTS
1 INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY DISORDERS
5.1 DEGENERATIVE DISEASES
5.2 NEUROTIC DISORDERS
5.3 PSYCHOSIS
5.4 OTHERS
6. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY TREATMENT
6.1 SHOCK TREATMENT
6.2 DRUG TREATMENT
6.3 OTHERS
7. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY END USER
7.1 HOSPITALS
7.2 CLINICS
7.3 RESEARCH CENTRES
7.4 OTHERS
8. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 WESTERN EUROPE
8.3.1.1 GERMANY
8.3.1.2 FRANCE
8.3.1.3 ITALY
8.3.1.3 SPAIN
8.3.1.5 UK
8.3.1.6 REST OF WESTERN EUROPE
8.3.2 EASTERN EUROPE
8.4 ASIA
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 AUSTRALIA
8.4.5 REPUBLIC OF KOREA
8.5 REST OF ASIA-PACIFIC
8.6 MIDDLE EAST & AFRICA
9. COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
9.1.1 STRATEGIC PARTNERSHIP
9.1.2 MERGER & ACQUISITION
10 COMPANY PROFILE
10.1 ASTRAZENECA
10.1.1 OVERVIEW
10.1.2 PRODUCT OVERVIEW
10.1.3 FINANCIALS
10.1.4 KEY DEVELOPMENTS
10.2 GLAXOSMITHKLINE
10.2.1 OVERVIEW
10.2.2 PRODUCT OVERVIEW
10.2.3 FINANCIALS
10.2.4 KEY DEVELOPMENTS
10.3 UNIVERSAL HEALTH SERVICES INC
10.3.1 OVERVIEW
10.3.2 PRODUCT OVERVIEW
10.3.3 FINANCIALS
10.3.4 STRATEGY
10.3.5 KEY DEVELOPMENT
10.4 BOEHRINGER INGELHEIM GMBH
10.4.1 OVERVIEW
10.4.2 PRODUCT OVERVIEW
10.4.3 FINANCIALS
10.4.4 KEY DEVELOPMENTS
10.5 ELI LILLY
10.5.1 OVERVIEW
10.5.2 PRODUCT OVERVIEW
10.5.3 FINANCIALS
10.5.4 KEY DEVELOPMENTS
10.6 OTHERS
11 CONCLUSION
11.1 KEY FINDINGS
11.1.1 FROM CEO’S VIEWPOINT
11.1.2 UNMET NEEDS OF THE MARKET
11.2 KEY COMPANIES TO WATCH
11.3 PREDICTION OF INDUSTRY
12 APPENDIX
Contact Info:
Name: Akash Anand
Email: Akash.Anand@Marketresearchfuture.Com
Organization: Market Research Future
Address: Market Research Future Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India
Phone: +1 646 845 9312
For more information, please visit https://www.marketresearchfuture.com/reports/neuropsychiatric-disorders-treatment-market-1281
Source: MarketersMedia
Release ID: 215237
Copyright © 1999-2013 SproutNews.com
